Bioassay Test Helps Diagnose Graves' Disease
By LabMedica International staff writers Posted on 15 Sep 2009 |
A new blood testing method specifically detects thyroid-stimulating immunoglobulins (TSIs), used to help identify Graves' disease.
The Thyretain TSI Reporter bioassay provides laboratories with the ability to test for TSI in the bloodstream using standard laboratory equipment, and unlike other nonspecific thyroid-related assays, does not require the use of radioactivity, and also eliminates ambiguity of test results that can be confounded by the presence of non-TSI autoantibodies. The kit includes a genetically engineered cell line that produces the reporter enzyme luciferase in response to specific TSI binding, and the amount of luciferase produced is then rapidly detected using a luminometer. The bioassay offers greater specificity because it only detects the TSI present in a patient's serum, aiding in a more accurate early diagnosis of Graves' disease. The Thyretain TSI Reporter bioassay was developed by Diagnostic Hybrids (Athens, OH, USA), and has been approved by the U.S. Food and Drug Administration (FDA).
"When used earlier when hyperthyroidism is first suspected, this assay may provide primary care physicians and patients alike reliable diagnostic information when classic symptoms of goiter or thyroid-related eye disease [ophthalmopathy] are absent,” said Jeff Houtz, senior product manager for Thyretain at Diagnostic Hybrids.
"Initial symptoms for thyroid disorders can often be nonspecific. By finding TSIs in patient serum, Thyretain is a rapid and reliable bioassay that provides a definitive assessment that could lead to earlier diagnosis of Graves' disease and better patient management,” said Frank Schwartz, M.D., a professor of endocrinology at the Ohio University College of Osteopathic Medicine (Northfield, USA).
Graves' disease is an autoimmune disease that most commonly affects the thyroid, frequently causing it to enlarge to twice its size or more (goiter) and become overactive, causing overstimulation of the thyroid gland and low thyroid-stimulating hormone (TSH) levels, a condition known as hyperthyroidism. Related symptoms such include increased heartbeat, muscle weakness, disturbed sleep, and irritability. It can also affect the eyes, causing bulging eyes (exophthalmos). It affects other systems of the body, including the skin, heart, circulation, and nervous system. Eighty percent of Graves' disease cases occur in women, and can be difficult to diagnose since symptoms vary greatly and often mimic other illnesses.
Related Links:
Diagnostic Hybrids
The Thyretain TSI Reporter bioassay provides laboratories with the ability to test for TSI in the bloodstream using standard laboratory equipment, and unlike other nonspecific thyroid-related assays, does not require the use of radioactivity, and also eliminates ambiguity of test results that can be confounded by the presence of non-TSI autoantibodies. The kit includes a genetically engineered cell line that produces the reporter enzyme luciferase in response to specific TSI binding, and the amount of luciferase produced is then rapidly detected using a luminometer. The bioassay offers greater specificity because it only detects the TSI present in a patient's serum, aiding in a more accurate early diagnosis of Graves' disease. The Thyretain TSI Reporter bioassay was developed by Diagnostic Hybrids (Athens, OH, USA), and has been approved by the U.S. Food and Drug Administration (FDA).
"When used earlier when hyperthyroidism is first suspected, this assay may provide primary care physicians and patients alike reliable diagnostic information when classic symptoms of goiter or thyroid-related eye disease [ophthalmopathy] are absent,” said Jeff Houtz, senior product manager for Thyretain at Diagnostic Hybrids.
"Initial symptoms for thyroid disorders can often be nonspecific. By finding TSIs in patient serum, Thyretain is a rapid and reliable bioassay that provides a definitive assessment that could lead to earlier diagnosis of Graves' disease and better patient management,” said Frank Schwartz, M.D., a professor of endocrinology at the Ohio University College of Osteopathic Medicine (Northfield, USA).
Graves' disease is an autoimmune disease that most commonly affects the thyroid, frequently causing it to enlarge to twice its size or more (goiter) and become overactive, causing overstimulation of the thyroid gland and low thyroid-stimulating hormone (TSH) levels, a condition known as hyperthyroidism. Related symptoms such include increased heartbeat, muscle weakness, disturbed sleep, and irritability. It can also affect the eyes, causing bulging eyes (exophthalmos). It affects other systems of the body, including the skin, heart, circulation, and nervous system. Eighty percent of Graves' disease cases occur in women, and can be difficult to diagnose since symptoms vary greatly and often mimic other illnesses.
Related Links:
Diagnostic Hybrids
Latest Molecular Diagnostics News
- Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
- Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
- Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
- Urine Test Diagnoses Early-Stage Prostate Cancer
- New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
- Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
- Revolutionary Blood Test Detects 30 Different Types of Cancers with 98% Accuracy
- Simple Blood Test Better Predicts Heart Disease Risk
- New Blood Test Detects 12 Common Cancers Before Symptoms Appear
- Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
- First-of-its-Kind Blood Test Detects Trauma-Related Diseases
- Key Gene Identified in Common Heart Disease Unlocks Life-Saving Diagnostic Potential
- Cheap Cell-Free DNA Based Test Accurately Predicts Preterm Birth
- RNA Blood Test Detects Cancers and Resistance to Treatment
- IL-6 Outperforms Traditional Tests for Early Sepsis Detection
- Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Channels
Clinical Chemistry
view channel
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more